Invega Sustenna Product Presentation
Invega Sustenna Product Presentation
Health and
Treatment wellness
continuation
Employment
Symptomatic Functional
remission improvement
Quality of Life
Tolerability
Social
integration
Outcome measures
Short-Term Long-term
1. Adapted from Nasrallah et al. Psychiatr Serv 2005;56:273–282. Defining and Measuring Clinical
Effectiveness in the Treatment of Schizophrenia.
Masalah utama dalam mencapai tujuan jangka
panjang terapi skizofrenia adalah KEPATUHAN
Paliperidone
Palmitate ester
Paliperidone Palmitate
1. INVEGA SUSTENNA Prescribing Information, March 2010. 2. Data on file, J&J PRD, LLC. Paliperidone: Investigator’s Brochure – Edition 9. February 25, 2009.
Document ID: EDMS-PSDB-913529:2:0. 3. Elan Drug Technologies (2009). Technology focus: helping you bring products to market [Brochure]. Dublin, Ireland. Available
at http://www.elandrugtechnologies.com/invisibleray/media/images/_client_specific/TechnologyFocus2.pdf. Accessed June 25, 2010.
Nyaman dengan dosis sebulan sekali
Perbandingan Paliperidone Palmitate dengan
LAI yang lain
Dosis maintenance Injeksi 1x per bulan Injeksi 1x per 2 minggu Umumnya 1x setiap 2-6 minggu
Placebo (n=160)
Paliperidone palmitate 25 mg eq. (n=155)
0 Paliperidone palmitate 100 mg eq. (n=161)
Mean change in PANSS total score
-6
-8
-10
-12
-14
-16 * * * * *
4 8 22 36 64 Endpoint
PANSS, Positive and Negative Syndrome Scale; • Efikasi terlihat secara signifikan sejak hari ke 8 pada pasien dengan
SE, standard error;
SD, standard deviation; LS, least squares
paliperidone palmitate vs placebo
• Tidak diperlukan suplementasi oral
*Due to the difference in median pharmacokinetic profiles between the 2 products, caution should be exercised when making a direct comparison
of their pharmacokinetic properties.
Paliperidone Palmitate efektif mencegah
relaps secara signifikan
100 ◎TIME TO
RELAPSE: Invega
Sustenna
Estimated % of patients
80
menunda waktu
without relapse
terjadinya relaps
60
secara signifikan
vs placebo
40
20
◎RELAPSE RATE:
Invega Sustenna® n=205 Angka kejadian
Placebo n=203 Log-rank test, p value <0.0001
relaps pada
0
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 Invega Sustenna
Days since randomization lebih rendah
Number of patients at risk
Time 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
secara signifikan
Placebo 203 192 163 136 121 101 84 71 58 47 37 34 22 13 9 6 6 vs Placebo
Paliperidone Palmitate 205 194 180 168 158 146 130 120 106 89 72 61 40 22 15 14 11
menunjukkan 65
kestabilan PANSS
Improvement
skor PBO/PP (n=153)
60
◎ Kelompok yang 55
mendapatkan placebo
tidak dapat mencapai
PP/PP (n=161)
level skor PANSS 50
yang sama bahkan NO DB/PP (n=74)
setelah mendapatkan 45
Paliperidone Palmitate BD 4 8 12 16 20 24 28 32 36 40 44 48 52 BO 4 8 12 16 20 24 28 32 36 40 4448
Weeks DB phase Weeks OLE phase
baseline to endpoint
8
8.3
Improvement
Dalam penelitian ini, *
Invega Sustenna® dosis 100– 6
150 mg menunjukkan 6.1
perbaikan signifikan skor PSP 4
vs placebo
2 2.9
1.7
0 Placebo 25 100 150
Paliperidone Palmitate dose (mg eq.)
*0.007 vs placebo; **<0.001 vs placebo
Study medication was administered as 4 doses: an initial deltoid IM injection of placebo or
Xeplion® 150 mg eq. followed by 3 fixed IM doses of placebo or Xeplion® (25, 100 or 150 mg eq.) on Days 8, 36 and 64
PSP, Personal and Social Performance scale; IM, intramuscular Pandina et al. J Clin Psychopharmacol 2010;30:235–244
Paliperidone memiliki profil tolerabilitas yang
relatif lebih baik dibandingkan antipsikotik atipikal
lainnya
Withdrew due to
0.88 2.09 1.07 0.74 0.93 1.02
AEs, %*
(0.71, 1.15) (0.8, 5.41) (0.65, 1.76) (0.38, 1.43) (0.66, 1.3) (0.83, 1.25)
(95% CI)
Kenaikan berat
1.75 3.08 4.56 3.15 3.12 2.84
badan≥7, %*
(1.29, 2.37) (1.53, 6.2) (3.46, 6.01) (2.33, 4.25) (1.84, 5.29) (2.3, 3.5)
(95% CI)
*OR for tolerability outcomes relative to placebo for different SGAs (lower scores are better)
◎ Efek samping yang paling umum (angka insiden ≥5% dan terjadi
setidaknya 2x lipat lebih banyak dibanding placebo) :*,†,1
– Reaksi pada tempat penyuntikan
– Somnolence (sedasi/mengantuk)
– Dizziness (pusing)
– Akathisia
– Gejala ekstrapiramidal
1. INVEGA® SUSTENNA® [US Prescribing Information]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2. Pandina GJ et al. J Clin
Psychopharmacol. 2010;30:235-244; 3. Gopal S et al. Int Clin Psychopharmacol. 2010;25:247-256;
75 mg eq. 75 mg eq.
150 mg eq. 100 mg eq. (Rekomendasi*) (Rekomendasi*)
Deltoid Deltoid
Deltoid/Gluteal Deltoid/Gluteal
± 1 minggu ± 1 minggu
Flexible dosing window Flexible dosing window
*Rekomendasi dosis bulanan
**Pasien dapat diberikandosis yang lebih tinggi atau lebih rendah berdasarkan respon individual terhadap efikasi dan/atau tolerabilotas
Paliperidone Palmitate
Tempat penyuntikan
Kozier et al. Fundamentals of nursing concepts, process and practice (5th ed).
IM, intramuscular Menlo Park, CA: Addison Wesley Longman, Inc; 1998 p784–785
Komponen dalam kemasan INVEGA
SUSTENNA
1 Prefilled syringe